RAFAEL CAPARICA BITTON
Índice h a partir de 2011
4
Projetos de Pesquisa
Unidades Organizacionais
ICESP-OS, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
bookPart Câncer de pulmão(2016) ROITBERG, Felipe Santa Rosa; BITTON, Rafael Caparica; CASTRO JUNIOR, Gilberto de- The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer(2016) PASSIGLIA, Francesco; CAPARICA, Rafael; GIOVANNETTI, Elisa; GIALLOMBARDO, Marco; LISTI, Angela; DIANA, Patrizia; CIRRINCIONE, Girolamo; CAGLEVIC, Christian; RAEZ, Luis E.; RUSSO, Antonio; ROLFO, ChristianIntroduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identified in several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potential role as oncogenic drivers and predictive biomarkers for targeted inhibition, leading to the clinical development of a new class of compounds blocking the NTRK molecular pathway, which are currently undner early clinical investigation. Area covered: This review describes the biology of the NTRK pathway and its molecular alterations in lung cancer. It focuses on the pre-clinical and clinical development of emerging NTRK inhibitors, which have shown very promising activity in early phase I studies. Expert opinion: Among the several NTRK-inhibitors, entrectinib and LOXO-101 are those in more advanced stage of clinical development. Both agents have shown encouraging activity along with a tolerable safety profile in patients with different solid tumors harboring NTRK-fusions, emerging as new promising therapeutic options for molecularly selected patients with advanced Trk-driven lung cancers. Results from ongoing phase II basket trials are eagerly awaited.
- BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?(2016) CAPARICA, Rafael; CASTRO JR., Gilberto de; GIL-BAZO, Ignacio; CAGLEVIC, Christian; CALOGERO, Raffaele; GIALLOMBARDO, Marco; SANTOS, Edgardo S.; RAEZ, Luis E.; ROLFO, ChristianB-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth and proliferation. In the present review, we discuss B-Raf mutation epidemiology, diagnostic methods to detect B-Raf mutations, the role of B-Raf as a driver mutation and a potential therapeutic target in NSCLC. The results of clinical trials involving B-Raf or MAPK pathway inhibitors for the treatment of NSCLC are also discussed. Clinical trials evaluating B-Raf inhibitors in BRAF mutated NSCLC patients have shown promising results, and larger prospective studies are warranted to validate these findings. Enrollment of these patients in clinical trials is an interesting strategy to offer a potentially more effective and less toxic targeted therapy.